DSGN Quote, Financials, Valuation and Earnings

Kodiak Sciences has a net margin of -- compared to Design Therapeutics's net margin of --. Design Therapeutics's return on equity of -- beat Kodiak Sciences's return on equity of --.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 82.42%. On the other hand Kodiak Sciences has an analysts' consensus of $7.25 which suggests that it could grow by 39.69%. Given that Design Therapeutics has higher upside potential than Kodiak Sciences, analysts believe Design Therapeutics is more attractive than Kodiak Sciences.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kodiak Sciences has a beta of 2.276, suggesting its more volatile than the S&P 500 by 127.607%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kodiak Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Kodiak Sciences pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Kodiak Sciences quarterly revenues of --. Design Therapeutics's net income of -$17.7M is higher than Kodiak Sciences's net income of -$57.5M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Kodiak Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus -- for Kodiak Sciences. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Design Therapeutics's net margin of -49.65%. Design Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 82.42%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Design Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Design Therapeutics is more attractive than NovaBay Pharmaceuticals.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Design Therapeutics's net income of -$17.7M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Design Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -- compared to Design Therapeutics's net margin of -67.73%. Design Therapeutics's return on equity of -- beat Quanterix's return on equity of -14.39%.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 82.42%. On the other hand Quanterix has an analysts' consensus of $11.00 which suggests that it could grow by 99.64%. Given that Quanterix has higher upside potential than Design Therapeutics, analysts believe Quanterix is more attractive than Design Therapeutics.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Quanterix has a beta of 1.127, suggesting its more volatile than the S&P 500 by 12.667%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Quanterix quarterly revenues of $30.3M. Design Therapeutics's net income of -$17.7M is higher than Quanterix's net income of -$20.5M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 1.58x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings has a net margin of -- compared to Design Therapeutics's net margin of -15.34%. Design Therapeutics's return on equity of -- beat Xeris Biopharma Holdings's return on equity of -1019.2%.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 82.42%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of $6.10 which suggests that it could grow by 20.46%. Given that Design Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Design Therapeutics is more attractive than Xeris Biopharma Holdings.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 0.700, suggesting its less volatile than the S&P 500 by 29.996%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Xeris Biopharma Holdings quarterly revenues of $60.1M. Design Therapeutics's net income of -$17.7M is lower than Xeris Biopharma Holdings's net income of -$9.2M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 3.52x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.